**America’s only Joint Commission-accredited radiopharmacy...

**America’s only Joint Commission-accredited radiopharmacy network distributing PET1, SPECT2 and therapeutic radiopharmaceuticals

**The acquisition significantly expands Telix’s North American manufacturing footprint

**build a radiometal production and distribution network for key therapeutic and diagnostic isotopes

**The acquisition also provides a clear pathway to extensively deploy Telix’s ARTMS QUANTM Irradiation System™ (QIS™) cyclotron technology, enabling standardised, high-efficiency and cost-effective production of radiometals.

** while broadening access for patients across the entire U.S. market, including under-served populations

**the transaction is expected to be cost-neutral to Telix

**31radiopharmacies covering more than 85% of the population

**Every RLS radiopharmacy is led by experienced nuclearpharmacists, who, along with nuclear technicians